This content is machine translated Atopic dermatitis Implement the “minimal disease activity” concept Minimal disease activity (MDA) in atopic dermatitis (AD) is a concept that combines a treat-to-target therapeutic strategy with the principle of shared decision-making. The aim is to achieve a state...…
View Post 12 min This content is machine translated Atopic dermatitis Clinic, therapy and prevention in early childhood Atopic dermatitis is the most common chronic inflammatory skin disease in early childhood and is caused by a complex interaction of genetic and environmental factors. The quality of life of...… CME-Test
View Post 9 min This content is machine translated SID Annual Meeting: Highlights Update on inflammatory dermatoses – a concentrated load of innovative power Research teams from different corners of the world presented studies that are characterized by a high level of innovation. In addition to the evaluation of already established therapy options, numerous...…
View Post 7 min This content is machine translated Atopic dermatitis and allergies Atopic dermatitis and allergies Type 2 inflammation and other factors Atopic patients are prone to immediate-type allergies and many studies show a correlation between sensitization to aeroallergens and exacerbations of atopic dermatitis (AD). A common characteristic of atopic diseases is...…
View Post 10 min This content is machine translated Atopic dermatitis in children New secondary analysis on dietary interventions A task force of the European Academy of Allergology and Clinical Immunology (EAACI) has compiled the current evidence on dietary interventions in pediatric AD patients who do not have food...…
View Post 4 min This content is machine translated Oral JAK-i in atopic dermatitis Benefits and risks: What does the current data say? Although there have been no recent approvals of oral JAK inhibitors (JAK-i) for atopic dermatitis (AD), some interesting study findings have been published. These shed light on the safety of...…
View Post 4 min This content is machine translated Biologics for atopic dermatitis Th2 cytokines in focus: proven and new targets The range of antibody therapies for atopic dermatitis (AD) has expanded once again in Europe. In addition to dupilumab and tralokinumab, lebrikizumab is another biologic available in this country that...…
View Post 4 min This content is machine translated Basic therapy for atopic dermatitis “Emollients plus” with bacterial lysates There are various indications in the specialist literature that the gram-negative, non-pathogenic bacterium Vitreoscilla filiformis (V. filiformis) has a beneficial effect on atopic skin. New findings confirm earlier reports of...…
View Post 6 min This content is machine translated Atopic dermatitis Biologics and JAK-i – the best of both worlds In Switzerland, both the currently approved monoclonal antibodies (dupilumab, tralokinumab, lebrikizumab) and the Janus kinase (JAK) inhibitors (baricitinib, abro-citinib, upadacitinib) can be used as “first-line” systemic therapy for patients with...…
View Post 6 min This content is machine translated Atopic dermatitis: "Treat-to-target" Current secondary analyses expand the evidence base In the recent past, several secondary analyses have been published in which different treatment regimes for atopic dermatitis (AD) were compared and evaluated. In order to evaluate treatment progress using…
View Post 8 min This content is machine translated Research highlights in atopic dermatitis Innovative therapies – Update 2024 The arsenal of currently researched active substances in the indication area of atopic dermatitis (AD) is considerable. In addition to anti-OX40/OX40L antibodies, CM310, nemolizumab and neurokinin receptor 1 antagonists, there…
